April 29th 2025
Downstaging and bridging strategies are changing how hepatocellular carcinoma (HCC) is treated.
Watch the series now!
JAMA Commentary Urges Realistic View of New CAR T-Cell Cancer Therapy
Nat Turner on Flatiron Health's Emphasis on Community Oncologists
Immune Adverse Events From Nivolumab Predict Better Survival With NSCLC
New CDC Report Provides Update on Incidence Rates of Pediatric ALL
First Anticancer Biosimilar Treatment Approved for Multiple Indications
Bringing Drugs to Market Costs Less Than Previously Thought, Study Finds
MACRA Survey Finds Oncology Physicians Unprepared for Payment Changes